Doxorubicin Transdrug®: Significant increased survival rate in patients with advanced hepatocellular carcinoma treated in a phase II clinical trial

BioAlliance Pharma SA (Euronext Paris – BIO), a company
dedicated to the treatment and supportive care of cancer and AIDS patients, today
announces positive survival data in its phase II clinical trial with doxorubicin Transdrug® in
patients with advanced hepatocellular carcinoma (primary liver cancer).
Doxorubicin Transdrug®, a treatment presented in the form of nanoparticles delivered via
hepatic intra-arterial route, was granted an orphan drug status in Europe and in the United
States. The product is being evaluated in patients with advanced hepatocellular carcinoma,
one of the leading causes of mortality in cancer.
BioAlliance Pharma phase II results showed a 88.9% survival rate after 18 months of
treatment in patients having received three intra-arterial doxorubicin Transdrug® injections,
as per protocol. This increased survival rate is relevant compared to the 54.5% rate observed
in patients with the current standard of care (usually transarterial chemoembolisation with a
cytotoxic drug).
Based on these data, BioAlliance Pharma will design new approaches using doxorubicin
Transdrug® while reducing pulmonary adverse events that led to the suspension of the trial.
“BioAlliance Pharma is capitalizing on its proprietary Transdrug® nanotechnology by
developing oral drug formulations”, said Dominique Costantini, President and CEO of
BioAlliance Pharma. “We are applying this innovative know-how to the treatment of various
cancers using oral irinotecan nanoparticles instead of intravenously administration.
BioAlliance Pharma aims at improving the irinotecan’s risk-benefit ratio and has recently
presented positive preclinical data at several international symposia”, added Dominique